Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy

M. S. Kaminski, C. N. Coleman, T. V. Colby, R. S. Cox, S. A. Rosenberg

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

The records of 148 consecutive patients with Ann Arbor stage I and II large-cell lymphoma treated with primary radiation therapy with or without adjuvant chemotherapy were analyzed retrospectively for pretreatment prognostic variables and results of treatment. For patients treated with radiation to fields on one side of the diaphragm, the 5-year freedom-from-relapse rate was 25% and the survival rate was 35%, but for those given additional transdiaphragmatic radiation or for those given radiation plus adjuvant chemotherapy, the rates were both approximately 67%. In a multivariate analysis, the only significant pretreatment prognostic variables were the number of sites of involvement and bulk of disease, with relapse as the endpoint. For patients treated with radiation to both sides of the diaphragm or with radiation plus adjuvant chemotherapy, the 5-year freedom-from relapse rate was 82% for the group with a favorable prognosis (with less than three sites of involvement and mass size of less than 10 cm) and 55% for those with an unfavorable prognosis.

Original languageEnglish (US)
Pages (from-to)747-756
Number of pages10
JournalAnnals of Internal Medicine
Volume104
Issue number6
StatePublished - 1986
Externally publishedYes

Fingerprint

Lymphoma
Radiotherapy
Radiation
Adjuvant Chemotherapy
Survival
Diaphragm
Recurrence
Multivariate Analysis
Survival Rate
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kaminski, M. S., Coleman, C. N., Colby, T. V., Cox, R. S., & Rosenberg, S. A. (1986). Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Annals of Internal Medicine, 104(6), 747-756.

Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. / Kaminski, M. S.; Coleman, C. N.; Colby, T. V.; Cox, R. S.; Rosenberg, S. A.

In: Annals of Internal Medicine, Vol. 104, No. 6, 1986, p. 747-756.

Research output: Contribution to journalArticle

Kaminski, MS, Coleman, CN, Colby, TV, Cox, RS & Rosenberg, SA 1986, 'Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy', Annals of Internal Medicine, vol. 104, no. 6, pp. 747-756.
Kaminski, M. S. ; Coleman, C. N. ; Colby, T. V. ; Cox, R. S. ; Rosenberg, S. A. / Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. In: Annals of Internal Medicine. 1986 ; Vol. 104, No. 6. pp. 747-756.
@article{1d605ed2be9f4d16a8ac0459a54a5a4d,
title = "Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy",
abstract = "The records of 148 consecutive patients with Ann Arbor stage I and II large-cell lymphoma treated with primary radiation therapy with or without adjuvant chemotherapy were analyzed retrospectively for pretreatment prognostic variables and results of treatment. For patients treated with radiation to fields on one side of the diaphragm, the 5-year freedom-from-relapse rate was 25{\%} and the survival rate was 35{\%}, but for those given additional transdiaphragmatic radiation or for those given radiation plus adjuvant chemotherapy, the rates were both approximately 67{\%}. In a multivariate analysis, the only significant pretreatment prognostic variables were the number of sites of involvement and bulk of disease, with relapse as the endpoint. For patients treated with radiation to both sides of the diaphragm or with radiation plus adjuvant chemotherapy, the 5-year freedom-from relapse rate was 82{\%} for the group with a favorable prognosis (with less than three sites of involvement and mass size of less than 10 cm) and 55{\%} for those with an unfavorable prognosis.",
author = "Kaminski, {M. S.} and Coleman, {C. N.} and Colby, {T. V.} and Cox, {R. S.} and Rosenberg, {S. A.}",
year = "1986",
language = "English (US)",
volume = "104",
pages = "747--756",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

TY - JOUR

T1 - Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy

AU - Kaminski, M. S.

AU - Coleman, C. N.

AU - Colby, T. V.

AU - Cox, R. S.

AU - Rosenberg, S. A.

PY - 1986

Y1 - 1986

N2 - The records of 148 consecutive patients with Ann Arbor stage I and II large-cell lymphoma treated with primary radiation therapy with or without adjuvant chemotherapy were analyzed retrospectively for pretreatment prognostic variables and results of treatment. For patients treated with radiation to fields on one side of the diaphragm, the 5-year freedom-from-relapse rate was 25% and the survival rate was 35%, but for those given additional transdiaphragmatic radiation or for those given radiation plus adjuvant chemotherapy, the rates were both approximately 67%. In a multivariate analysis, the only significant pretreatment prognostic variables were the number of sites of involvement and bulk of disease, with relapse as the endpoint. For patients treated with radiation to both sides of the diaphragm or with radiation plus adjuvant chemotherapy, the 5-year freedom-from relapse rate was 82% for the group with a favorable prognosis (with less than three sites of involvement and mass size of less than 10 cm) and 55% for those with an unfavorable prognosis.

AB - The records of 148 consecutive patients with Ann Arbor stage I and II large-cell lymphoma treated with primary radiation therapy with or without adjuvant chemotherapy were analyzed retrospectively for pretreatment prognostic variables and results of treatment. For patients treated with radiation to fields on one side of the diaphragm, the 5-year freedom-from-relapse rate was 25% and the survival rate was 35%, but for those given additional transdiaphragmatic radiation or for those given radiation plus adjuvant chemotherapy, the rates were both approximately 67%. In a multivariate analysis, the only significant pretreatment prognostic variables were the number of sites of involvement and bulk of disease, with relapse as the endpoint. For patients treated with radiation to both sides of the diaphragm or with radiation plus adjuvant chemotherapy, the 5-year freedom-from relapse rate was 82% for the group with a favorable prognosis (with less than three sites of involvement and mass size of less than 10 cm) and 55% for those with an unfavorable prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0022634894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022634894&partnerID=8YFLogxK

M3 - Article

C2 - 3518561

AN - SCOPUS:0022634894

VL - 104

SP - 747

EP - 756

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -